Research Papers:

O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis

Congxin Dai _, Bowen Sun, Xiaohai Liu, Xinjie Bao, Ming Feng, Yong Yao, Junji Wei, Kan Deng, Chengxian Yang, Xueyuan Li, Wenbin Ma and Renzhi Wang

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:19674-19683. https://doi.org/10.18632/oncotarget.14936

Metrics: PDF 1444 views  |   HTML 1864 views  |   ?  


Congxin Dai1,*, Bowen Sun1,*, Xiaohai Liu1, Xinjie Bao1, Ming Feng1, Yong Yao1, Junji Wei1, Kan Deng1, Chengxian Yang1, Xueyuan Li1, Wenbin Ma1, Renzhi Wang1

1Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

*These authors have contributed equally to this work

Correspondence to:

Renzhi Wang, email: [email protected]

Keywords: pituitary adenomas, MGMT, recurrence, aggressive

Received: October 07, 2016    Accepted: December 01, 2016    Published: February 01, 2017


O-6-methylguanine-DNA methyltransferase (MGMT) reportedly counteracts the cytotoxic effects of the alkylating agent temozolomide. MGMT expression is often low in aggressive pituitary adenomas (PAs) and recurrent PAs. However, because these associations are controversial, we performed this meta-analysis to clarify the involvement of MGMT in the prognosis and clinicopathology of PA. We searched for relevant studies in electronic databases (MEDLINE, the Cochrane Library Database, EMBASE, CINAHL, Web of Science and the Chinese Biomedical Database (CBD)) and calculated/pooled the odds ratios (ORs) or standard mean differences (SMDs) with 95% confidence intervals (95% CIs). Eleven case-control studies with a total of 454 PA patients were included. Our meta-analysis revealed that lower expression of MGMT was associated with PA recurrence (OR=2.09, 95% CI=1.09–4.02; p=0.026). On the other hand, MGMT expression was not associated with PA invasiveness (OR=1.112, 95% CI=0.706–1.753; p=0.646), Unexpectedly, MGMT expression could not be used to distinguish functional from non-functional PA patients (OR=1.766, 95% CI=0.938–3.324; p=0.078). The MGMT expression was not found to be related to other clinicopathological indicators of PA including age, gender or tumor size. No publication bias was detected in this meta-analysis (p>0.05). This meta-analysis suggests that MGMT expression may be associated with PA tumor recurrence, but not be related to invasiveness or other clinicopathological indicators. Thus, detection of MGMT expression may facilitate outcome prediction and guide clinical therapy for PA patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14936